Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Annamycin in Refractory or Relapsed ALL
NCT00271063Phase 2Unknown
- Sponsor
- Callisto Pharmaceuticals, Inc.
- Start
- Oct 2005
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of annamycin in acute lymphoblastic leukemia (ALL), sponsored by Callisto Pharmaceuticals, Inc. Primary endpoints: Safety and tolerability of L-Annamycin at 8 months and Maximum Tolerated Dose at 8 months. Status: unknown.
02
Drugs
annamycin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00271063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00271063.